BRISTOL MYERS SQUIBB CO
BMYAPI behind this page
BMY FY 2025 request
Playground key active
/api/financials?ticker=BMY&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 48,194 | 48,300 | -0.2% |
Show Product Lines breakouts |
|||
| Abecma | 427 | 406 | +5.2% |
| Abraxane | 368 | 875 | -57.9% |
| Alliance and other revenues | 1,438 | 1,522 | -5.5% |
| Alliance revenues | 447 | 479 | -6.7% |
| Alliance revenues · Collaborative Arrangement | 447 | 479 | -6.7% |
| Breyanzi | 1,358 | 747 | +81.8% |
| Camzyos | 1,068 | 602 | +77.4% |
| Cobenfy | 155 | 10 | +1450.0% |
| Eliquis | 14,443 | 13,333 | +8.3% |
| Gross product sales | 88,085 | 83,671 | +5.3% |
| Growth Portfolio | 26,409 | 22,563 | +17.0% |
| Krazati | 205 | 126 | +62.7% |
| Legacy Portfolio | 21,785 | 25,737 | -15.4% |
| Net product sales | 46,756 | 46,778 | -0.0% |
| Net product sales · Collaborative Arrangement | 14,588 | 13,587 | +7.4% |
| Net product sales · Ono | 178 | 158 | +12.7% |
| Net product sales · Pfizer | 14,328 | 13,187 | +8.7% |
| Opdivo | 10,049 | 9,304 | +8.0% |
| Opdivo Qvantig | 238 | — | — |
| Opdualag | 1,185 | 928 | +27.7% |
| Orencia | 3,705 | 3,682 | +0.6% |
| Other Growth products | 1,924 | 1,643 | +17.1% |
| Other Legacy products | 798 | 925 | -13.7% |
| Other revenues | 992 | 1,043 | -4.9% |
| Pomalyst/Imnovid | 2,733 | 3,545 | -22.9% |
| Reblozyl | 2,327 | 1,773 | +31.2% |
| Revlimid | 2,951 | 5,773 | -48.9% |
| Sotyktu | 291 | 246 | +18.3% |
| Sprycel | 493 | 1,286 | -61.7% |
| Yervoy | 2,900 | 2,530 | +14.6% |
| Zeposia | 577 | 566 | +1.9% |
Show Geography breakouts |
|||
| Non Us | 13,828 | 13,199 | +4.8% |
| Other | 1,087 | 996 | +9.1% |
| US | 33,279 | 34,105 | -2.4% |
Show Alliances and Collaboration Companies [Axis] breakouts |
|||
| Ono | 510 | 491 | +3.9% |
| Ono · Collaborative Arrangement | 331 | 333 | -0.6% |
| Pfizer | 14,443 | 13,333 | +8.3% |
| Pfizer · Collaborative Arrangement | 115 | 146 | -21.2% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 15,035 | 14,066 | +6.9% |
| Cost of Revenue | 13,936 | 13,968 | -0.2% |
Show Alliances and Collaboration Companies [Axis] breakouts |
|||
| Pfizer · Collaborative Arrangement | 6,980 | 6,419 | +8.7% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 7,181 | 6,597 | +8.9% |
| Selling, General & Administrative | 7,267 | 8,414 | -13.6% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 267 | 295 | -9.5% |
| Research & Development | 9,951 | 11,159 | -10.8% |
Show Alliances and Collaboration Companies [Axis] breakouts |
|||
| Janssen · Collaborative Arrangement | 277 | 274 | +1.1% |
Show Nature Of Expense breakouts |
|||
| Drug Development | 4,550 | 4,495 | +1.2% |
| Other | 4,060 | 5,142 | -21.0% |
| Other Research | 1,341 | 1,522 | -11.9% |
| Acquired I P R D | 3,721 | 13,373 | -72.2% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 3,721 | 13,373 | -72.2% |
| Amortizationof Acquired Intangible Assets | 3,317 | 8,872 | -62.6% |
| Other Non-Operating Income (Expense) | 674 | 893 | -24.5% |
Show Alliances and Collaboration Companies [Axis] breakouts |
|||
| Pfizer · Collaborative Arrangement | -42 | -42 | 0.0% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | -23 | -137 | +83.2% |
| Total Costs & Expenses | 38,866 | 56,679 | -31.4% |
| Income Before Taxes | 9,328 | -8,379 | +211.3% |
| Income Tax Expense (Benefit) | 2,272 | 554 | +310.1% |
| Net Income | 7,055 | -8,933 | +179.0% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 2 | 15 | -86.7% |
| Retained Earnings | 7,054 | -8,948 | +178.8% |
| Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest | 2 | 15 | -86.7% |
| Net Income | 7,054 | -8,948 | +178.8% |
| EPS (Basic) | 3.47 | -4.41 | +178.7% |
| EPS (Diluted) | 3.46 | -4.41 | +178.5% |
| Interest Expense | 1,891 | 1,947 | -2.9% |
| Interest Income | -586 | -478 | -22.6% |
| Comprehensive Income | 6,767 | -8,640 | +178.3% |
| Wtd Avg Shares (Basic) | 2,034 | 2,027 | +0.3% |
| Wtd Avg Shares (Diluted) | 2,039 | 2,027 | +0.6% |
| Marketing And Advertising Expense | 1.3 | 1.5 | -13.3% |
| Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax | -267 | 409 | -165.3% |
| Income Loss From Equity Method Investments | -47 | -44 | -6.8% |
| Gain Loss On Investments | -280 | -16 | -1650.0% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 10,209 | 10,346 | -1.3% |
| Available For Sale Securities Debt Securities Current | 464 | 513 | -9.6% |
| Receivables Net Current | 11,414 | 10,747 | +6.2% |
Show Alliances and Collaboration Companies [Axis] breakouts |
|||
| Pfizer · Collaborative Arrangement | 176 | 189 | -6.9% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 198 | 221 | -10.4% |
| Inventory | 2,690 | 2,557 | +5.2% |
| Other Assets Current | 4,613 | 5,617 | -17.9% |
| Total Current Assets | 29,390 | 29,780 | -1.3% |
| Accounts Receivable | 9,592 | 9,012 | +6.4% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 7,543 | 7,136 | +5.7% |
Show Geography breakouts |
|||
| Non Us | 2,612 | 2,322 | +12.5% |
| US | 4,931 | 4,814 | +2.4% |
| Goodwill | 21,754 | 21,719 | +0.2% |
| Deferred Tax Assets | 5,378 | 4,236 | +27.0% |
| Available For Sale Securities Debt Securities Noncurrent | 396 | 320 | +23.8% |
| Other Non-Current Assets | 6,474 | 6,105 | +6.0% |
| Total Assets | 90,038 | 92,603 | -2.8% |
| Operating Lease Right-of-Use Assets | 1,582 | 1,224 | +29.2% |
Show Lease Contractual Term breakouts |
|||
| Commencement of San Diego Lease | 370 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 19,103 | 23,307 | -18.0% |
Show Finite Lived Intangible Assets By Major Class breakouts |
|||
| Computer Software Intangible Asset | 389 | 400 | -2.8% |
| Licensing Agreements | 1,375 | 1,705 | -19.4% |
| Technology Based Intangible Assets | 9,739 | 13,217 | -26.3% |
Show Indefinite Lived Intangible Assets By Major Class breakouts |
|||
| In Process Research And Development | 7,600 | 7,985 | -4.8% |
| Current Liabilities | |||
| Debt Current | 2,261 | 2,046 | +10.5% |
| Accounts Payable | 3,575 | 3,602 | -0.7% |
Show Alliances and Collaboration Companies [Axis] breakouts |
|||
| Pfizer · Collaborative Arrangement | 1,599 | 1,463 | +9.3% |
Show Type Of Arrangement breakouts |
|||
| Collaborative Arrangement | 1,684 | 1,578 | +6.7% |
| Other Liabilities Current | 17,581 | 18,126 | -3.0% |
| Total Current Liabilities | 23,417 | 23,774 | -1.5% |
| Current Portion of Long-Term Debt | 1,977 | 1,828 | +8.2% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 222 | 369 | -39.8% |
| Long-Term Debt | 42,850 | 47,603 | -10.0% |
| Other Non-Current Liabilities | 5,043 | 4,469 | +12.8% |
| Total Liabilities | 71,533 | 76,215 | -6.1% |
| Long-Term Debt | 44,827 | 49,431 | -9.3% |
Show Debt Instrument breakouts |
|||
| 3.200% To 6.875% For Notes Due 2026 To 2097 | 8,712 | — | — |
| Operating Lease Liabilities | 1,826 | 1,370 | +33.3% |
| Accrued Income Taxes Noncurrent | 1,407 | 1,491 | -5.6% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 292 | 292 | 0.0% |
| Additional Paid-In Capital | 46,387 | 46,024 | +0.8% |
| Accumulated Other Comprehensive Income | -1,524 | -1,238 | -23.1% |
| Retained Earnings | 16,896 | 14,912 | +13.3% |
| Treasury Stock Common Value | -43,579 | -43,655 | +0.2% |
| Total Stockholders' Equity | 18,473 | 16,335 | +13.1% |
| Minority Interest | 33 | 53 | -37.7% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18,506 | 16,388 | +12.9% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -1,524 | -1,238 | -23.1% |
| Additional Paid In Capital | 46,387 | 46,024 | +0.8% |
| Common Stock | 292 | 292 | 0.0% |
| Noncontrolling Interest | 33 | 53 | -37.7% |
| Retained Earnings | 16,896 | 14,912 | +13.3% |
| Treasury Stock Common | -43,579 | -43,655 | +0.2% |
| Total Liabilities & Equity | 90,038 | 92,603 | -2.8% |
| Preferred Stock Shares Outstanding | 2,510 | 2,868 | -12.5% |
| Preferred Stock Shares Issued | 2,510 | 2,868 | -12.5% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 4,011 | 9,600 | -58.2% |
| Deferred Income Taxes | -965 | -2,089 | +53.8% |
| Stock-Based Compensation | 553 | 507 | +9.1% |
| Impairment Of Long Lived Assets To Be Disposed Of | 1,098 | 2,963 | -62.9% |
| Divestiture Gains And Royalties | -1,165 | -1,119 | -4.1% |
| Equity Method Investment Realized Gain Loss On Disposal | -280 | -16 | -1650.0% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | 351 | — | — |
Show Contingent Consideration By Type breakouts |
|||
| Contingent value rights | 351 | — | — |
| Other Non-Cash Items | 232 | 94 | +146.8% |
| Increase Decrease In Receivables | -295 | 264 | -211.7% |
| Change in Inventory | -184 | -486 | +62.1% |
| Change in Accounts Payable | -2 | 184 | -101.1% |
| Increase Decrease In Other Accrued Liabilities | -441 | 1,484 | -129.7% |
| Increase Decrease In Accrued Income Taxes Payable | -4 | -1,260 | +99.7% |
| Increase Decrease In Other Operating Capital Net | 471 | 624 | -24.5% |
| Net Cash from Operations | 14,156 | 15,190 | -6.8% |
| Investing Activities | |||
| Proceeds From Sale And Maturity Of Available For Sale Securities | 1,975 | 1,122 | +76.0% |
| Payments To Acquire Marketable Securities | -2,000 | -769 | -160.1% |
| Proceeds From Sale Of Equity Securities Fv Ni | 77 | 265 | -70.9% |
| Capital Expenditures | -1,311 | -1,248 | -5.0% |
| Divestiture And Other Proceeds | 1,071 | 1,099 | -2.5% |
| Payments To Acquire Businesses Net Of Cash Acquired | -3,944 | -21,821 | +81.9% |
| Net Cash from Investing | -4,132 | -21,352 | +80.6% |
| Financing Activities | |||
| Proceeds From Other Short Term Debt | 25 | 99 | -74.7% |
| Proceeds From Issuance Of Long Term Debt | 5,740 | 12,883 | -55.4% |
| Repayments Of Long Term Debt | -10,940 | -2,873 | -280.8% |
| Payments Of Dividends | -5,045 | -4,863 | -3.7% |
| Payments For Proceeds From Stock Option Exercises And Other Adjustments | -128 | -106 | -20.8% |
| Net Cash from Financing | -10,348 | 5,127 | -301.8% |
| Supplemental | |||
| Income Taxes Paid | 3,264 | 3.9 | +83592.3% |
| Interest Paid | 2.1 | 1.8 | +16.7% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 195 | -137 | +242.3% |
| Net Change in Cash | -129 | -1,172 | +89.0% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 10,218 | 10,347 | -1.2% |
Values in millions USD. Source: SEC EDGAR 10-K filing.